Biosimilars: the need, the challenge, the future: the FDA perspective

Area of Science:

• Biopharmaceutical development
• Regulatory science
• Drug approval processes

Background:

• The biosimilars industry has emerged due to the financial success and patent expirations of biologic therapies.
• Biosimilars aim to provide lower-cost alternatives to existing biologic agents.
• Unlike generic drugs, biosimilars may exhibit structural and functional differences from their reference products.

Purpose of the Study:

• To summarize the history of the biosimilars industry.
• To outline the U.S. Food and Drug Administration's (FDA) regulations and guidance for biosimilar development.
• To identify challenges in bringing biosimilars to market.

Main Methods:

• Review of current literature on biosimilars.
• Analysis of existing regulations and FDA guidance documents.
• Interpretation of financial and clinical implications of biosimilars.

Main Results:

• The U.S. Food and Drug Administration (FDA) has not yet approved any biosimilar via the abbreviated licensure pathway.
• New FDA guidance outlines processes for demonstrating biosimilarity or interchangeability with reference biologics.
• Complex large-molecule biosimilars may face lengthy FDA approval processes, potentially hindering cost reduction efforts.

Conclusions:

• Biosimilar development is driven by the economic landscape of biologic drugs.
• The pharmaceutical industry must innovate analytical methods to prove similarity for complex biosimilars.
• Emerging "biobetter" or "biosuperior" drugs represent advancements beyond simple mimicry of existing biologics.